COPENHAGEN, November 18, 2025: Novo Nordisk has reduced the direct-to-consumer price of its weight-loss drug Wegovy and most doses of its diabetes treatment Ozempic to $349 per month in the United States. The move marks one of the most significant pricing adjustments by the Danish pharmaceutical company as it broadens access to its semaglutide-based medicines.
The new monthly price applies to cash-paying patients purchasing directly through Novo Nordisk’s programs or participating pharmacy partners. Previously, Wegovy had been priced at around $499 per month for uninsured patients. The reduction precedes the implementation of a broader cost agreement with the U.S. government that aims to make weight-loss and diabetes treatments more affordable.
Novo Nordisk confirmed that all standard doses of Ozempic will now be available at the $349 price point, with the exception of the highest 2 milligram dose, which will remain at $499. The adjustment takes effect immediately and will be available nationwide through the company’s direct-purchase platform, NovoCare, and participating distributors including GoodRx, Costco, and WeightWatchers.
In addition to the standard pricing, Novo Nordisk introduced a limited-time introductory offer for new customers. Patients starting on the two lowest doses of Wegovy or Ozempic will be eligible for an introductory rate of $199 per month through March 31, 2026. This initiative is designed to expand patient access for those without insurance coverage and simplify the purchase process through retail and online channels.
U.S. price agreement targets fairer drug cost structure
The pricing changes are part of Novo Nordisk’s compliance with a cost framework established under a recent agreement with the U.S. government. The framework, known informally as “TrumpRx,” seeks to reduce out-of-pocket drug prices for consumers and set voluntary pricing caps for GLP-1-based medications. Under the agreement, manufacturers are expected to offer average monthly cash prices around $350 or lower, with further reductions anticipated for publicly insured patients by mid-2026.
Novo Nordisk stated that the adjustment will make semaglutide treatments more accessible for individuals managing obesity and type 2 diabetes. The company said it continues to expand production capacity to meet growing demand for GLP-1 therapies, which have seen global uptake since the introduction of Wegovy and Ozempic in recent years. The U.S. market remains the largest for both drugs, with millions of prescriptions written annually.
According to Novo Nordisk’s latest earnings report, semaglutide-based products account for a substantial share of its overall revenue, reflecting the increasing medical and consumer interest in weight management therapies. The new pricing is expected to simplify purchasing for patients outside traditional insurance coverage and improve transparency in drug pricing. Medical professionals have noted that while the new $349 monthly price is lower than before, the cost still presents a barrier for many patients without comprehensive insurance.
Rollout positions Novo Nordisk for expanded U.S. reach
However, patient advocacy groups have acknowledged the move as a step toward expanding affordability in a fast-growing therapeutic category. With the new pricing structure now in place, Novo Nordisk is expected to continue working with retail partners and healthcare providers to ensure consistent product availability. The company reiterated that the adjustments apply to both current and new patients purchasing directly through eligible channels and that all U.S. shipments under the new pricing are effective immediately.
The latest announcement follows months of discussion between major drugmakers and U.S. regulators over reducing out-of-pocket expenses for patients using GLP-1 treatments. The change places Novo Nordisk’s pricing for Wegovy and most Ozempic doses below the $350 benchmark set in its agreement with U.S. authorities, establishing a new standard for direct-access drug pricing in the weight-loss and diabetes care market. – By Content Syndication Services.